Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:35:55 16/01/2026 GMT			5-day change	1st Jan Change
41.52 ^EUR	-1.38%		+6.78%	+12.17%

01-16	Health Care Up as Wegovy Pill Buoys Novo Nordisk -- Health Care Roundup	DJ
01-16	Bayer welcomes US Supreme Court decision to review Durnell case in Roundup litigation	RE

BAYER AG : Upgraded to Buy by JP Morgan

Published on 12/08/2025 at 07:21 am GMT

MarketScreener with dpa-AFX Analyser

Bayer AG

-1.38%

JP Morgan's analyst Richard Vosser upgrades his rating from Neutral to Buy. Previously set at EUR 25, the target price has been raised to EUR 50.

Latest news about Bayer AG

01-16	Health Care Up as Wegovy Pill Buoys Novo Nordisk -- Health Care Roundup	DJ
01-16	Bayer welcomes US Supreme Court decision to review Durnell case in Roundup litigation	RE
01-16	Bayer AG - Company expects a decision on merits during court's 2026 session, which ends in June	RE
01-16	Bayer AG - U.S. Supreme Court today announced that it will review Durnell Roundup case	RE
01-16	US Supreme Court to hear Bayer's bid to curb Roundup cases	RE
01-16	U.S. Supreme Court agrees to hear Bayer's bid to limit lawsuits filed under state laws over its weedkiller Roundup	RE
01-16	Bayer's Eylea Secures EU Approval for Retinal Vein Occlusion	MT
01-16	MWB Research Upgrades Bayer to Buy, Boosts PT	MT
01-16	Bayer Receives EU Approval for High-Dose Eylea in Another Indication	DP
01-16	Bayer says Eylea 8 mg approved in the EU for third retinal indication	RE
01-16	BAYER AG : UBS sticks Neutral	ZD
01-16	Dax Expected to Open Lower – Inflation and Auto Sector in Focus	RE
01-15	Bayer Upgraded to Buy as mwb Notes 'Improving Medium-term Risk-Reward'	MT
01-15	European Midday Briefing : Shares Rise; Gold and Oil Fall on Easing U.S.-Iran Tensions	DJ
01-14	German DAX Index Slips; Bayer, RWE Shares Surge	MT
01-14	Frankfurt Stocks Close: DAX Ends Impressive Record-Breaking Streak	DP
01-14	Orion Sees Long-Term Nubeqa Sales Surpassing 1 Billion Euros – Issues 2026 Forecast (Update)	FW
01-14	Orion Estimates to Hit Annual Net Sales Target for Nubeqa by Decade-end	MT
01-14	Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug	DJ
01-14	Bayer Continues Recovery Rally – Sees Major Pharma Potential Ahead	DP
01-14	Ipsen and EMS-Chemie Shine on the Stock Market, Vistry and Pearson Struggle
01-14	Bayer Sees Pharmaceutical Business on Growth Trajectory	DP
01-14	U.S. Futures Fall, Precious Metals Gain on Iranian Unrest	DJ
01-14	Historic Morning Record for the CAC 40
01-14	Bayer Targets Around 30 Percent Margin for Pharma Division by 2030	RE

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38.9%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.6%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.2%), Switzerland (1.2%), Europe/Middle East/Africa (23.6%), the United States (31.7%), North America (3.6%), China (7.7%), Asia/Pacific (9.6%), Brazil (9.3%) and Latin America (8.1%).

Employees

88,502

Sector

Pharmaceuticals

Calendar

01-18 - Kepler Cheuvreux German Corporate Conference

More about the company